87N Stock Overview
Engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Stevanato Group S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.50 |
| 52 Week High | US$32.60 |
| 52 Week Low | US$17.50 |
| Beta | 0.76 |
| 1 Month Change | -29.44% |
| 3 Month Change | -37.50% |
| 1 Year Change | -28.86% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 5.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| 87N | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -5.9% | -2.9% | -0.9% |
| 1Y | -28.9% | -14.0% | 4.5% |
Return vs Industry: 87N underperformed the German Life Sciences industry which returned -14% over the past year.
Return vs Market: 87N underperformed the German Market which returned 4.5% over the past year.
Price Volatility
| 87N volatility | |
|---|---|
| 87N Average Weekly Movement | 9.6% |
| Life Sciences Industry Average Movement | 6.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 87N's share price has been volatile over the past 3 months.
Volatility Over Time: 87N's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 5,635 | Franco Moro | www.stevanatogroup.com |
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines.
Stevanato Group S.p.A. Fundamentals Summary
| 87N fundamental statistics | |
|---|---|
| Market cap | €4.84b |
| Earnings (TTM) | €136.18m |
| Revenue (TTM) | €1.08b |
35.5x
P/E Ratio4.5x
P/S RatioIs 87N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 87N income statement (TTM) | |
|---|---|
| Revenue | €1.08b |
| Cost of Revenue | €757.43m |
| Gross Profit | €325.93m |
| Other Expenses | €189.75m |
| Earnings | €136.18m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.50 |
| Gross Margin | 30.09% |
| Net Profit Margin | 12.57% |
| Debt/Equity Ratio | 26.9% |
How did 87N perform over the long term?
See historical performance and comparison